Final answer:
The p-value of 0.1494 at the 5 percent significance level indicates that there is no significant difference between Vraylar-treated patients and placebo-treated patients concerning the changes in total fasting cholesterol, fasting triglycerides, and fasting glucose.
Step-by-step explanation:
When evaluating the statement that percentages of Vraylar-treated patients with shifts from normal to high and borderline to high in total fasting cholesterol, fasting triglycerides, and fasting glucose were similar to placebo-treated patients, we must look into the statistical analysis of the data from a clinical study. If the p-value is reported as 0.1494 and we are testing at the 5 percent significance level, we can conclude that there is insufficient evidence to support a significant difference between the two treatments. This implies that the percentage of Vraylar-treated patients experiencing shifts in these parameters is similar to those seen in placebo-treated patients, in line with the True/False question at the start.
Understanding this relies on knowledge of statistical hypothesis testing, which can also be applied to a range of other scenarios presented, such as assessing the effectiveness of a low-fat diet or new diet in lowering cholesterol, the significance of increases in adipocytokines, or understanding Type I and Type II errors in the context of clinical trial results